VYNE Therapeutics Inc

NASDAQ:VYNE   3:59:52 PM EDT
1.57
+0.09 (+6.08%)
4:16:51 PM EDT: $1.55 -0.02 (-1.27%)
Restructuring / Reorganization, Other Pre-Announcement

VYNE Therapeutics Reports Q2 Revenues Of $4.3 Mln

Published: 08/12/2021 11:47 GMT
VYNE Therapeutics Inc (VYNE) - Vyne Therapeutics Reports Second Quarter 2021 Financial Results and Announces New Strategic Direction to Develop Treatments for Immunological and Inflammatory Diseases.
Vyne Therapeutics Inc Says Co Has Initiated Process to Explore a Sale Or License of Its Topical Minocycline Franchise.
Vyne Therapeutics Inc Quarterly Loss per Share $0.39.
Vyne Therapeutics Inc Quarterly Adjusted Loss per Share $0.35.
Vyne Therapeutics Inc Quarterly Revenues $4.3 Million Compared to $11.7 Million Last Year.